Oncotarget

Research Papers:

Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR

Nicolas Macagno, Frédéric Fina, Nicolas Penel, Corinne Bouvier, Isabelle Nanni, Florence Duffaud, Raquel Rouah, Bruno Lacarelle, L'houcine Ouafik, Sylvie Bonvalot and Sébastien Salas _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:18296-18308. https://doi.org/10.18632/oncotarget.24817

Metrics: PDF 1661 views  |   HTML 3290 views  |   ?  


Abstract

Nicolas Macagno1,2,*, Frédéric Fina1,3,*, Nicolas Penel4, Corinne Bouvier1,2, Isabelle Nanni5, Florence Duffaud6,7, Raquel Rouah5, Bruno Lacarelle8, L'houcine Ouafik5, Sylvie Bonvalot9 and Sébastien Salas6,7

1Department of Pathology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France

2Aix-Marseille University, Medical Faculty, CRO2, UMR 911 (Equipe IV), Marseille, France

3ID-Solutions, Grabels, France

4Department of General Oncology, Oscar Lambret Center, Lille, France

5Department of Molecular Oncology, Assistance Publique Hôpitaux de Marseille, Marseille, France

6Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France

7Aix-Marseille University, Medical Faculty, Marseille, France

8Department of Medical Biology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France

9Department of Surgery, Institut Curie, PSL Univeristy, Paris, France

*These authors contributed equally to this work

Correspondence to:

Sébastien Salas, email: [email protected]

Keywords: ddPCR; cfDNA; CTNNB1; desmoid; prognosis

Received: October 27, 2017     Accepted: February 25, 2018     Published: April 06, 2018

ABSTRACT

Since desmoid tumors (DT) exhibit an unpredictable clinical course, with stabilization and/or spontaneous regression, an initial “wait-and-see” policy is the new standard of care–thus, the actual challenge is to identify early factors of progression.

We present a method of detection of CTNNB1 mutations using a targeted digital droplet PCR (ddPCR) on cell-free DNA (cfDNA) extracted from blood samples of 31 DT patients. Furthermore, we analyzed the correlation between DT evolution and plasmatic concentration of total and mutated cfDNA at the time of diagnosis.

Circulating copies of CTNNB1 mutants (ctDNA) were detected in the plasma of 6 patients (33%) but their concentration was not correlated with evolution of the tumor. Concentration of total cfDNA was higher in the plasma of patients with progressive desmoids (p = 0,0009). Using a threshold <900 copies/mL of plasma to detect indolent desmoid and a threshold >1375, it was possible to predict desmoid evolution for 65% of patients by measuring the quantity of circulating DNA in their plasma as early as the time of diagnosis.

Albeit showing that the detection of CTNNB1 mutants is possible in the plasma of patients harboring a desmoid tumor, the results of this preliminary study raise the hypothesis that most of the circulating DNA detected in their plasma is derived from non-neoplastic cells, most likely normal neighboring tissues being actively invaded. Our results open the perspective of using cfDNA as a biomarker to predict prognosis at the time of diagnosis and assess tumor dynamics to optimize the treatment strategy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24817